Navigation Links
Nephros Reports Second Quarter 2011 Financial Results
Date:8/15/2011

g statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements include statements regarding the efficacy and intended use of our technologies under development, the timelines for bringing such products to market and the availability of funding sources for continued development of such products and other statements that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that:

  • we may not be able to continue as a going concern;
  • we may not be able to obtain funding if and when needed or on terms favorable to us in order to continue operations;
  • we may not obtain appropriate or necessary regulatory approvals to achieve our business plan or effectively market our products including, without limitation, FDA approval of our HDF system;
  • products that appeared promising to us in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials;
  • we may encounter problems with our suppliers and manufacturers;
  • we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
  • HDF therapy may not be accepted in the United States and/or our technology and
    '/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
4. Nephros Signs Development Agreement with STERIS
5. Nephros Reports 2010 First Quarter Financial Results
6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
8. Nephros Reports 2010 Second Quarter Financial Results
9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
10. Nephros Reports 2010 Third Quarter Financial Results
11. Nephros Rights Offering Registration Statement Declared Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Jazz Pharmaceuticals plc ... will report its 2014 second quarter financial results on ... financial markets.  Company management will host a live audio ... p.m. IST to provide a business and financial update ... Interested parties may access the live audio webcast via ...
(Date:7/22/2014)... 2014  Decision Resources Group finds that the market for ... will remain relatively stagnant at a value of around $80 ... coronary intervention (PCI) volumes are growing faster in ... the United States and ... the increase in penetration of PCI procedures relative to coronary ...
(Date:7/22/2014)... ALBANY, New York , July 22, 2014 ... published by Transparency Market Research "Process Spectroscopy Market (Technology Types ... infrared (FT-IR) spectroscopy) Market - Global Industry Analysis, Size, Share, ... valued at USD 714.5 million in 2012 and is expected ... 2019. North America was ...
Breaking Medicine Technology:Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4
... , , New collaborative research program to study effects ... Dec. 30 A new research program called the Medication ... to study the effects of prescription medications used during pregnancy. ... Drug Administration and researchers at the HMO Research Network Center ...
... , BOSTON, Dec. 30 Solos Endoscopy, Inc. (Pink ... to a prosperous 2010, following a solid year in 2009, due ... the closing months of 2009, Solos Endoscopy, Inc. has taken the ... of surgical endoscopy instruments. This will allow the MammoView(TM) line to ...
Cached Medicine Technology:FDA, Health Organizations to Study Safety of Medications Taken During Pregnancy 2FDA, Health Organizations to Study Safety of Medications Taken During Pregnancy 3Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010 2
(Date:7/22/2014)... American Society of Hematology (ASH) will honor Michael DeBaun, ... Robert P. Hebbel, MD, of the University of Minnesota ... Prize for their significant research advances in the area ... named for the late Ernest Beutler, MD, a past ... years, is a two-part lectureship that recognizes major translational ...
(Date:7/22/2014)... Marc, Ph.D., director of research at the University of ... by the International Society of Eye Research (ISER) as ... 2014 Paul Kayser International Award in Retina Research., The ... has made a significant contribution to the understanding of ... this week at the ISER Biennial Meeting in San ...
(Date:7/22/2014)... D.C. (PRWEB) July 22, 2014 ... “Ensuring Seniors Access to Local Pharmacies Act of ... Medicare Part D would undermine the availability of ... spending by $21 billion over the next 10 ... Company released by the Pharmaceutical Care Management Association ...
(Date:7/22/2014)... may share certain pathogenic mechanisms with cancer, according to ... Linda Kusner, Ph.D. , published in PLOS ... work shows that the very same inhibitors of apoptosis, ... cells that produce autoimmune diseases. Henry Kaminski, M.D. ... GW School of Medicine and Health Sciences (SMHS), as ...
(Date:7/22/2014)... July 22, 2014 The Beryl Institute ... third annual Institute Scholar Program. These offerings reinforce the ... patient experience in healthcare and the need for rigorous ... grant and scholar programs are intended to ... Value of focusing on the patient experience before, ...
Breaking Medicine News(10 mins):Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3
... they took the advice of the government in refusing to ... three children. Swindon NHS chiefs said that the denial of ... advice from their superiors.// ,Herceptin is not licensed ... are suing the NHS for its failure to provide the ...
... the National Heart, Lung, and Blood Institute (NHLBI), has ... high blood pressure., ,The education would be given ... who have been trained to educate other physicians in ... help doctors and patients prevent and better treat high ...
... disease), Russia has put a stop and a aban on ... animal feed from the Argentine province of Corrientes. The action ... by the the Agriculture Ministry of Russia. ,The ... health body), about an outbreak of the disease in cattle ...
... vaccine in the US is expected to enhance the supply ... preparation. Currently, the Australian manufacturer, //CSL, is selling the flu ... to a Swiss based Berna Biotech enables distribution of the ... have expressed hope over initiation of clinical trials in the ...
... immediately after birth may be the best indicator of subsequent ... fatigues two weeks after the birth of their child were ... mothers are tired right after having a baby - it ... and heal from the physical and mental stressors of childbirth," ...
... University Medical Center have found that the lethal impact ... anticipated. Researchers from the Mailman School of Public Health ... study, which// appears in the February issue of Diabetes ... and treat periodontal disease should be considered a standard ...
Cached Medicine News:Health News:Extension Education for Blood Pressure advice! 2Health News:Persistent Fatigue Could Be An Early Indicator Of Postpartum Depression 2Health News:Gum Disease Affects Diabetic Children Earlier Than Anticipated 2
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
... the most advanced image-guided platforms available ... of an expandable platform. In addition ... supports new applications in electromagnetics (EM). ... well as the ability to track ...
... The Mayfield 2000 series radiolucent headrest system ... intraoperative digital subtraction angiography. This system is ... skull clamp and the Mayfield radiolucent base ... designed for patient positioning in the prone ...
Bunnel hand drill with Jacobs chuck, chuck size 4 mm....
Medicine Products: